279 related articles for article (PubMed ID: 23856420)
41. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation.
Matern D; Seydewitz HH; Bali D; Lang C; Chen YT
Eur J Pediatr; 2002 Oct; 161 Suppl 1():S10-9. PubMed ID: 12373566
[TBL] [Abstract][Full Text] [Related]
42. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
[No Abstract] [Full Text] [Related]
43. Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.
Kang HR; Gjorgjieva M; Smith SN; Brooks ED; Chen Z; Burgess SM; Chandler RJ; Waskowicz LR; Grady KM; Li S; Mithieux G; Venditti CP; Rajas F; Koeberl DD
Mol Ther Methods Clin Dev; 2019 Dec; 15():383-391. PubMed ID: 31890731
[TBL] [Abstract][Full Text] [Related]
44. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
[TBL] [Abstract][Full Text] [Related]
45. Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
Gjorgjieva M; Calderaro J; Monteillet L; Silva M; Raffin M; Brevet M; Romestaing C; Roussel D; Zucman-Rossi J; Mithieux G; Rajas F
J Hepatol; 2018 Nov; 69(5):1074-1087. PubMed ID: 30193922
[TBL] [Abstract][Full Text] [Related]
46. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
Saeed A; Hoogerland JA; Wessel H; Heegsma J; Derks TGJ; van der Veer E; Mithieux G; Rajas F; Oosterveer MH; Faber KN
Hum Mol Genet; 2020 Jan; 29(2):264-273. PubMed ID: 31813960
[TBL] [Abstract][Full Text] [Related]
47. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
Waskowicz LR; Zhou J; Landau DJ; Brooks ED; Lim A; Yavarow ZA; Kudo T; Zhang H; Wu Y; Grant S; Young SP; Huat BB; Yen PM; Koeberl DD
Hum Mol Genet; 2019 Jan; 28(1):143-154. PubMed ID: 30256948
[TBL] [Abstract][Full Text] [Related]
48. Recent development and gene therapy for glycogen storage disease type Ia.
Chou JY; Kim GY; Cho JH
Liver Res; 2017 Sep; 1(3):174-180. PubMed ID: 29576889
[TBL] [Abstract][Full Text] [Related]
49. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
Cho JH; Lee YM; Bae SH; Chou JY
Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334
[TBL] [Abstract][Full Text] [Related]
50. Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia.
Lee YM; Conlon TJ; Specht A; Coleman KE; Brown LM; Estrella AM; Dambska M; Dahlberg KR; Weinstein DA
J Inherit Metab Dis; 2018 Nov; 41(6):977-984. PubMed ID: 29802554
[TBL] [Abstract][Full Text] [Related]
51. Gene therapy for type I glycogen storage diseases.
Chou JY; Mansfield BC
Curr Gene Ther; 2007 Apr; 7(2):79-88. PubMed ID: 17430128
[TBL] [Abstract][Full Text] [Related]
52. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas.
Mutel E; Abdul-Wahed A; Ramamonjisoa N; Stefanutti A; Houberdon I; Cavassila S; Pilleul F; Beuf O; Gautier-Stein A; Penhoat A; Mithieux G; Rajas F
J Hepatol; 2011 Mar; 54(3):529-37. PubMed ID: 21109326
[TBL] [Abstract][Full Text] [Related]
53. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing.
Rutten MGS; Derks TGJ; Huijkman NCA; Bos T; Kloosterhuis NJ; van de Kolk KCWA; Wolters JC; Koster MH; Bongiovanni L; Thomas RE; de Bruin A; van de Sluis B; Oosterveer MH
Hepatology; 2021 Nov; 74(5):2491-2507. PubMed ID: 34157136
[TBL] [Abstract][Full Text] [Related]
54. Mutational analysis and clinical investigations of medically diagnosed GSD 1a patients from Pakistan.
Gul B; Firasat S; Shan T; Tehreem R; Afshan K
PLoS One; 2023; 18(11):e0288965. PubMed ID: 38033126
[TBL] [Abstract][Full Text] [Related]
55. Heterogeneous mutations in the glucose-6-phosphatase gene in Japanese patients with glycogen storage disease type Ia.
Takahashi K; Akanuma J; Matsubara Y; Fujii K; Kure S; Suzuki Y; Wataya K; Sakamoto O; Aoki Y; Ogasawara M; Ohura T; Miyabayashi S; Narisawa K
Am J Med Genet; 2000 May; 92(2):90-4. PubMed ID: 10797430
[TBL] [Abstract][Full Text] [Related]
56. G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a.
Roseman DS; Khan T; Rajas F; Jun LS; Asrani KH; Isaacs C; Farelli JD; Subramanian RR
Mol Ther; 2018 Mar; 26(3):814-821. PubMed ID: 29428299
[TBL] [Abstract][Full Text] [Related]
57. The molecular basis of type 1 glycogen storage diseases.
Chou JY
Curr Mol Med; 2001 Mar; 1(1):25-44. PubMed ID: 11899241
[TBL] [Abstract][Full Text] [Related]
58. The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia.
Gautam S; Zhang L; Arnaoutova I; Lee C; Mansfield BC; Chou JY
Hum Mol Genet; 2020 Mar; 29(5):834-844. PubMed ID: 31961433
[TBL] [Abstract][Full Text] [Related]
59. Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy.
Kim GY; Kwon JH; Cho JH; Zhang L; Mansfield BC; Chou JY
Hum Mol Genet; 2017 May; 26(10):1890-1899. PubMed ID: 28334808
[TBL] [Abstract][Full Text] [Related]
60. Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia.
La Rose AM; Bazioti V; Hoogerland JA; Svendsen AF; Groenen AG; van Faassen M; Rutten MGS; Kloosterhuis NJ; Dethmers-Ausema B; Nijland JH; Mithieux G; Rajas F; Kuipers F; Lukens MV; Soehnlein O; Oosterveer MH; Westerterp M
Mol Metab; 2021 Nov; 53():101265. PubMed ID: 34091064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
